Table 2 Restricted NY-ESO-1 gene expression in normal cells or tissues treated with the decitabine.

From: Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype

Type of therapy

Type of cancer

Type of normal cells or tissues and clinical study

Side effects

Reference

High-affinity NY-ESO-1157-165 TCR-T cells plus decitabine

Acute myeloid leukemia

AML blasts, normal cell lines; in vitro

Undetectable NY-ESO-1mRNA and protein levels

Present study

NY-ESO-1-specific T cells plus decitabine

Multiple myeloma

Clinical study (NCT01050790)

Safe and feasible

[54]

NY-ESO-1157-165 TCR-T cells plus decitabine

Colorectal cancer

Fibroblasts (skin, colon)

Negligible effects

[55]

NY-ESO-1157-165 TCR-T cells plus decitabine

Thoracic cancer

Bronchial epithelia

Safe and feasible

[56]

NY-ESO-1specific CTLs plus decitabine

Glioma

Astrocyte cells,

Undetectable NY-ESO-1 in human normal cells

[58]

NY-ESO-1 specific CD8 + T cells, CD4 + T cells; NY-ESO-1 Vaccine plus decitabine

Ovarian cancer

Clinical study (NCT00887796)

Safe and feasible

[59]

DEC-205/NY-ESO-1 specific CD8 + T cells, CD4 + cells NY-ESO-1 Vaccine plus decitabine

Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)

Clinical study (NCT 01834248)

Safe and feasible

[62]

Back to article page